Aligos Therapeutics, Inc. (ALGS) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US01626L2043

Price
2.10 USD
Market cap
20.76 m USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

Aligos Therapeutics, Inc. financials

Fiscal year2025
Revenue2.19 m USD
Operating income-87.99 m USD
EBIT-23.88 m USD
Net income-24.19 m USD
Diluted EPS – continuing operations-2.45 USD

Full history since 2018, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Aligos Therapeutics, Inc.

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.